Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes

References

• Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: no easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182–186.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. 2020. Available at: https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PDFW090120.pdf. Accessed January 23, 2021.
   Google Scholar
• Perlman DC, Jordan AE. The syndemic of opioid misuse, overdose, HCV, and HIV: structural-level causes and interventions. Curr HIV/AIDS Rep. 2018;15(2):96–112.
   PubMed Web of Science ®Google Scholar
• Horton R. Offline: COVID-19 is not a pandemic. Lancet. 2020;396(10255):874.
   PubMed Web of Science ®Google Scholar
• Singer M, Bulled N, Ostrach B, Mendenhall E. Syndemics and the biosocial conception of health. Lancet. 2017;389(10072):941–950.
   PubMed Web of Science ®Google Scholar
• Del Pozo B, Beletsky L, Rich JD. COVID-19 as a frying pan: the promise and perils of pandemic-driven reform. J Addict Med. 2020;14(5):e144–e146.
   PubMed Web of Science ®Google Scholar
• Linas BP, Savinkina A, Barbosa C, et al. A clash of epidemics: impact of the COVID-19 pandemic response on opioid overdose. J Subst Abuse Treat. 2021;120:108158.
   PubMed Web of Science ®Google Scholar
• Khatri UG, Perrone J. Opioid use disorder and COVID-19: crashing of the crises. J Addict Med. 2020;14(4):e6–e7.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. Heal Alert Netw. 2020. Available at: https://emergency.cdc.gov/han/2020/han00438.asp. Accessed December 31, 2020.
   Google Scholar
• Wen LS, Sadeghi NB. The opioid crisis and the 2020 US election: crossroads for a national epidemic. Lancet. 2020;396(10259):1316–1318.
   PubMed Web of Science ®Google Scholar
• Glei DA, Preston SH. Estimating the impact of drug use on US mortality, 1999–2016. Silva JP, ed. PLoS One. 2020;15(1):e0226732.
   PubMed Web of Science ®Google Scholar
• National Academy of Medicine, Leshner AI, Manche M. Medications for opioid use disorder save lives (Leshner AI, Mancher M, eds.). Washington, DC: National Academies Press; 2019.
   Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55–e63.
   PubMed Web of Science ®Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
   PubMed Web of Science ®Google Scholar
• Levin FR, Bisaga A, Sullivan MA, Williams AR, Cates-Wessel K. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic. Am J Addict. 2016;25(8):603–609.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Mannelli P, Sullivan MA, et al. Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies. Am J Addict. 2018;27(3):177–187.
   PubMed Web of Science ®Google Scholar
• Jaffe JH, O’Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003;70(2 suppl):S3–S11.
   PubMedGoogle Scholar
• Fornili KS, Fogger SA. Nurse practitioner prescriptive authority for buprenorphine: from DATA 2000 to CARA 2016. J Addict Nurs. 2017;28(1):43–48.
   PubMed Web of Science ®Google Scholar
• Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine. Can Fam Physician. 2012;58(1):37–41.
   PubMedGoogle Scholar
• Bhatraju EP, Grossman E, Tofighi B, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract. 2017;12(1):7.
   PubMedGoogle Scholar
• Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341:c5475.
   PubMed Web of Science ®Google Scholar
• Dupouy J, Palmaro A, Fatséas M, et al. Mortality associated with time in and out of buprenorphine treatment in french office-based general practice: a 7-year cohort study. Ann Fam Med. 2017;15(4):355–358.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–120.
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426–430.
   PubMed Web of Science ®Google Scholar
• Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What actually works? A systematic review. PLoS One. 2017;12(10):e0186315.
   PubMed Web of Science ®Google Scholar
• Olfson M, Zhang V, Schoenbaum M, King M. Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff. 2020;39(6):984–992.
   Web of Science ®Google Scholar
• Shover CL, Falasinnu TO, Dwyer CL, et al. Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance. Drug Alcohol Depend. 2020;216:108314.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Martin SA, Chiodo LM, Wilson A. Retention in care as a quality measure for opioid use disorder. Subst Abus. 2019;40(4):453–458.
   PubMed Web of Science ®Google Scholar
• Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17.
   PubMed Web of Science ®Google Scholar
• Neumann AM, Blondell RD, Azadfard M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav. 2013;38(11):2724–2728.
   PubMed Web of Science ®Google Scholar
• Stein BD, Sorbero M, Dick AW, Pacula RL, Burns RM, Gordon AJ. Physician capacity to treat opioid use disorder with buprenorphine-assisted treatment. JAMA. 2016;316(11):1211–1212.
   PubMed Web of Science ®Google Scholar
• Olfson M, Zhang VS, Schoenbaum M, King M. Trends in buprenorphine treatment in the United States, 2009–2018. JAMA. 2020;323(3):276–277.
   PubMed Web of Science ®Google Scholar
• HHS, CMS, PQMM. Quality ID #468 (NQF 3175): continuity of pharmacotherapy for Opioid Use Disorder (OUD). 2019. Available at: https://qpp.cms.gov/docs/QPP_quality_measure_specifications/CQM-Measures/2019_Measure_468_MIPSCQM.pdf. Accessed October 22, 2020.
   Google Scholar
• Abraham AJ, Adams GB, Bradford AC, Bradford WD. County-level access to opioid use disorder medications in medicare Part D (2010–2015). Health Serv Res. 2019;54(2):390–398.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Lin LA, Bohnert ASB, Goldstick JE. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw Open. 2019;2(6):e196373.
   PubMed Web of Science ®Google Scholar
• Flavin L, Malowney M, Patel NA, et al. Availability of buprenorphine treatment in the 10 states with the highest drug overdose death rates in the United States. J Psychiatr Pract. 2020;26(1):17–22.
   PubMed Web of Science ®Google Scholar
• McGinty EE, Stone EM, Kennedy-Hendricks A, Bachhuber MA, Barry CL. Medication for opioid use disorder: a national survey of primary care physicians. Ann Intern Med. 2020;173(2):160–162.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Doyle E, Kreiner PW, et al. Prescribing patterns of buprenorphine waivered physicians. Drug Alcohol Depend. 2017;181:213–218.
   PubMed Web of Science ®Google Scholar
• Sigmon SC The untapped potential of office-based buprenorphine treatment. JAMA Psychiatry. 2015;72(4):395–396.
   PubMed Web of Science ®Google Scholar
• Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113–121.
   PubMed Web of Science ®Google Scholar
• Marino LA, Campbell AN, Nunes EV, Sederer LI, Dixon LB. Factors influencing buprenorphine prescribing among physicians in New York State. J Addict. 2019;2019:7832752–7832755.
   PubMedGoogle Scholar
• Zhou C, Crawford A, Serhal E, Kurdyak P, Sockalingam S. The impact of project ECHO on participant and patient outcomes: a systematic review. Acad Med. 2016;91(10):1439–1461.
   PubMed Web of Science ®Google Scholar
• Sockalingam S, Arena A, Serhal E, Mohri L, Alloo J, Crawford A. Building provincial mental health capacity in primary care: an evaluation of a project ECHO Mental Health Program. Acad Psychiatry. 2018;42(4):451–457.
   PubMed Web of Science ®Google Scholar
• Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199–2207.
   PubMed Web of Science ®Google Scholar
• Eaton L. Hierarchy disruptors: bringing specialist knowledge from hospital to community care. BMJ. 2019;365:l4376.
   PubMedGoogle Scholar
• Tofighi B, Isaacs N, Byrnes-Enoch H, et al. Expanding treatment for opioid use disorder in publicly funded primary care clinics: exploratory evaluation of the NYC health+hospitals buprenorphine ECHO program. J Subst Abuse Treat. 2019;106:1–3.
   PubMed Web of Science ®Google Scholar
• Komaromy M, Duhigg D, Metcalf A, et al. Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016;37(1):20–24.
   PubMed Web of Science ®Google Scholar
• Martin SA, Chiodo LM, Bosse JD, Wilson A. The next stage of buprenorphine care for opioid use disorder. Ann Intern Med. 2018;169(9):628–635.
   PubMed Web of Science ®Google Scholar
• Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health. 2011;38(2):65–76.
   PubMed Web of Science ®Google Scholar
• Delivery System Reform Incentive Payment (DSRIP) Program. 2020. Available at: https://www.health.ny.gov/health_care/medicaid/redesign/dsrip/. Accessed July 16, 2020.
   Google Scholar
• Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020;173(1):57–58.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. HHS expands access to treatment for opioid use disorder. 2021. Available at: https://www.hhs.gov/about/news/2021/01/14/hhs-expands-access-to-treatment-for-opioid-use-disorder.html. Accessed January 25, 2021.
   Google Scholar
• Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2019;46(3):273–288.
   PubMed Web of Science ®Google Scholar
• Salvador J, Bhatt S, Fowler R, et al. Engagement with project echo to increase medication-assisted treatment in rural primary care. Psychiatr Serv. 2019;70(12):1157–1160.
   PubMed Web of Science ®Google Scholar
• Weinstein LC, Iqbal Q, Cunningham A, et al. Retention of patients with multiple vulnerabilities in a federally qualified health center buprenorphine program: Pennsylvania, 2017–2018. Am J Public Health. 2020;110(4):580–586.
   PubMed Web of Science ®Google Scholar